                         Page 10                                                   New Application: Revised 09-[ADDRESS_1224335] block 
for postoperative analgesia for open abdominal hysterectomies 
 
Clinical Trials registration number:  [STUDY_ID_REMOVED] 
 
Document date: 6/22/2016  
  
                         Page 11                                                   New Application: Revised 09-[ADDRESS_1224336] HEALTH SYSTEM IRB PROTOCOL FORMAT  
Appendix 1  
(Incomplete applications will be returned, & inadequate responses may lead to a delay in review.)You may mark your responses in the 
shaded areas following each question.  Supporting documents (articles, drug toxicity information, etc.) must be submitted when applicable.  
A "See Attached" response will not be accepted for review.  Be concise & clear.  
  
Directions:  
Sponsored protocol: If you have a sponsored protocol (e.g., pharmaceutical), a grant application (e.g., National 
Institutes of Health), or another peer-reviewed protocol, you may submit that protocol/application along with the 
application elements.  It is the responsibility of the Principal Investigator [INVESTIGATOR_876445], however, that the 
protocol/application contains the information requested in this "IRB Protocol Format".  Additional sheets should be 
attached to the protocol/application as necessary to provide the information (e.g., a description of the process of 
consent) required for IRB review.  When available, the Investigator's Brochure must be submitted along with the 
research protocol, or a summary of the preclinical/animal data and any relevant clinical data.    
  
Physician Initiated protocol:  If you have not been provided a protocol from an outside source, you must develop one. 
The following is the "Henry Ford Health System â€œIRB Protocol Format".  
  
1. PURPOSE:  State in one or two sentences the purpose or objective of this project.  The goal of this study is to evaluate the 
effectiveness of different formulations of bupi[INVESTIGATOR_876446] (TAP) on post-
operative pain management after open abdominal hysterectomy.  
  
2. SPECIFIC AIMS:  Number your aims so that the aims can be referred to in the Project Design and Data Analysis sections 
of this outline. 1) To determine if a TAP block with liposomal bupi[INVESTIGATOR_876447]-operative analgesia 
after open abdominal hysterectomy.  2) To determine if the mixing of liposomal bupi[INVESTIGATOR_876448] a TAP block.  
  
3. RATIONALE FOR THE PROJECT:  
a. State the rationale for the project and support it with background information about the project. Critically evaluate 
existing knowledge, and specifically identify the gaps in knowledge the project will fill.  Liposomal  
bupi[INVESTIGATOR_14072] a novel formulation of the local anesthetic bupi[INVESTIGATOR_876449] [ADDRESS_1224337]-operative analgesia after robotic prostatectomy, laparoscopic colorectal surgery, 
and abdominal hernia repair; however, those studies did not compare the effectiveness of liposomal bupi[INVESTIGATOR_876450].  Our experience at 
Henry Ford Hospi[INVESTIGATOR_876451]. This year, a randomized controlled single blinded study comparing liposomal bupi[INVESTIGATOR_876452] [ADDRESS_1224338]-operatively in the liposomal bupi[INVESTIGATOR_124195].    
b. State the applicant's prior research and experience in this research area. As a quality improvement initiative, we have 
retrospectively reviewed the effectiveness of TAP blocks with liposomal bupi[INVESTIGATOR_876453]-operative analgesia after laparoscopic asissted colectomy and open abdominal hysterectomy.  As members of 
the regional anesthesia division, we have extensive experience performing TAP blocks for a wide range of abdominal 
surgical procedures.  
  
4. SIGNIFICANCE:  State concisely the importance of this project by [CONTACT_564157], long-  
      range objectives.  Providing optimal post-operative analgesia to our patients is important to improve  
                         Page 12                                                   New Application: Revised 09-[ADDRESS_1224339]:    
a. State the inclusion and exclusion criteria for enrollment of subjects.   Inclusion criteria: elective open abdominal 
hysterectomy with a midline incision, age>18, ASA 1-3.  Exclusion criteria: patient with a chronic pain condition,  
major unexpected surgical complication, unexpected prolonged intubation, patient refusal, local anesthetic allergy, 
any contraindication to regional anesthesia, and greater than two attempts for TAP block by [CONTACT_876458].      
b. Describe the control population (if utilized) and justify its selection.Our current standard practice is to use 0.25% 
bupi[INVESTIGATOR_354951], therefore, the control population is the group receiving 0.25% Bupi[INVESTIGATOR_10319].  
c. Support the likelihood of recruiting the number of subjects required to complete the project.  Relate this to other 
projects recruiting similar subjects.We estimate that 100-[ADDRESS_1224340] Hospi[INVESTIGATOR_39191].  We anticipate an 80% or higher recruitment rate.  Therefore, we 
anticipate recruiting [ADDRESS_1224341] DESIGN AND PROTOCOL:    
a. Describe the experimental design/methodology.Prospective randomized observer-blinded controlled study.   
b. Outline the protocol, corresponding it to the specific aims; identify the data or endpoints to be analyzed to reach the 
specific aims. All eligible patients will be seen in the pre-operative holding area to discuss the study.  Informed 
consent will be obtained at that time.  The patient will be randomized to one of three groups by [CONTACT_876459]. Group 1 will receive a TAP block with a total of 60 mL 0.25% bupi[INVESTIGATOR_40473].  Group 2 will 
receive a TAP block with a total of 20 mL of liposomal bupi[INVESTIGATOR_23183] 40 mL normal saline.  Group 3 will receive a 
TAP block with a total of 20 mL of liposomal bupi[INVESTIGATOR_23183] 40 mL 0.25% bupi[INVESTIGATOR_40473].  Our 
standard sedation protocol for all patients receiving any nerve block is to provide a maximum of [ADDRESS_1224342]-anesthesia care unit (PACU), and one time during each of the following time periods: 0-[ADDRESS_1224343] opi[INVESTIGATOR_40499], and pain score during the above mentioned time periods.  
Secondary outcomes are patient satisfaction, length of stay in hospi[INVESTIGATOR_307], timing of ambulation, presence of nausea and 
vomiting, evidence of local anesthetic toxicity and any postoperative hemodynamic instability.    
c. Discuss potential limitations and difficulties in the protocol.We don't anticipate any difficulties with this protocol 
since patients typi[INVESTIGATOR_128788] a TAP block for post-operative analgesia for open abdominal hysterectomy at Henry 
Ford Hospi[INVESTIGATOR_307].  One limitation of our protocol is that it is not double-blinded.  Liposomal bupi[INVESTIGATOR_876454].  Therefore, the anesthesiologist performing the block cannot be blinded to 
group selection.  All other care team members including anesthesia team, surgical team, and floor nurses, will be 
blinded to the group selection.   
d. Provide a tentative schedule for conducting and completing this project and, if applicable, the multicenter study.We 
anticipate one year to recruit patients and collect data.  Data analysis will take a few months after study completion.  
e. Data collection: Submit a copy of the data collection tool or list the data fields to be collected (review IRB policy, 
Access to Medical Records for Research).Age, ASA classification, height, weight, BMI, indication for hysterectomy, 
surgeon, duration of surgery, time of TAP block, time to first break-through analgesic, cumulative analgesic doses  
and pain scores at rest and with movement in PACU and in the following time periods: 0-[ADDRESS_1224344] 24hrs,then every 12 hrs for the next 24 hours.  Satisfaction (ie not satisfied, 
satisfied, very satisfied), length of stay in the hospi[INVESTIGATOR_307], presence of ambulation, presence of nausea and vomiting, 
evidence of local anesthetic toxicity, presence of hypotension.  
  
7. DATA ANALYSIS:  Describe the analysis of the data and relate this to the specific aims in detail. Case reports and 
medical record reviews also require a description of the planned data analysis (ie. descriptive, observational). The 
Committee recommends free consultation with the Division of Biostatistics and Research Epi[INVESTIGATOR_876455]. Many clinical measurements will be recorded post operation. Some are one-time measurements such as total 
opi[INVESTIGATOR_8556], and some are repeated measurements such as pain scores. Total 8-9 measuring times for those 
                         Page 13                                                   New Application: Revised 09-[ADDRESS_1224345] deviation and range. Frequency 
counts and percentage will be provided for categorical data. Estimates for averages and proportions will also include 95 % 
confidence intervals. One-way Analysis of Variance( ANOVA ) will be used to assess the efficacy of three anesthetic 
bupi[INVESTIGATOR_876456] ( G1: bupi[INVESTIGATOR_301537]; G2: liposomal bupi[INVESTIGATOR_10319] ; G3: liposomal bupi[INVESTIGATOR_10319] + bupi[INVESTIGATOR_149146] ) on total opi[INVESTIGATOR_8556], patient satisfaction,  length of stay in hospi[INVESTIGATOR_876457]. 
Generalized Estimating Equations ( GEE ) will be utilized to evaluate the effects of these three anesthetic formulas on 
repeated measures of pain scores, presence of nausea and vomiting, evidence of local anesthetic toxicity and any 
postoperative hemodynamic instability. Cox proportion hazard models will be applied to assess the effect of these 
anesthetic formulas on the time to first opi[INVESTIGATOR_40499]. The statistical analysis will be obtained by [CONTACT_4696] 9.4 
and the tests are claimed to be significant if the p- values are less than 0.05.   
  
8. JUSTIFICATION FOR NUMBER OF SUBJECTS OR DATA:    
  
a. State the number of subjects or data points to be analyzed in the project at this institution and the total number for 
multicenter studies. The Committee recommends consultation with the Division of Biostatistics and Research 
Epi[INVESTIGATOR_623] ([PHONE_18162]. Total [ADDRESS_1224346] 80% recruitment rate of total 100-[ADDRESS_1224347] Hospi[INVESTIGATOR_39191].  
b. Describe the statistical justification for this number of subjects or data points.Total 90 patients ( 30 for each of these 3 
groups ) will have 80% power to detect the effect size of 0.[ADDRESS_1224348] ANOVA for assessing the effects of 
three formulas on total opi[INVESTIGATOR_8556]; and an effect size of 0.24 can be detected with 80% power assuming 0.[ADDRESS_1224349] HEALTH SYSTEM (IRB) DRUG/SUBSTANCE INFORMATION   
(This form must be completed for each individual drug or substance -investigational or  marketed- that is 
being administered as part of this research study)  
  
1.  Generic/Chemical Name: [CONTACT_326794][INVESTIGATOR_10319]   2. Trade Name: [CONTACT_124210]  
3.  Manufacturer: Pacira Pharmaceuticals  4. Mode of Administration:   other: infiltrated into the 
transversus abdominus plane  
5.  How Supplied (dose form & strength): 20 ML vials 
containing 266 mg liposomal bupi[INVESTIGATOR_10319].  6. Who will be administer the drug/substance? Staff 
anesthesiologist and resident anesthetist  
7.  Dosage and Schedule Proposed:Groups 2 and 3 will receive 20 mL liposomal bupi[INVESTIGATOR_57270] a one time injection for a 
TAP block.  
8.  Will you be utilizing research pharmacy for storage or dispensing of any medication? (if this is an inpatient study, you 
are required to use research pharmacy).    Yes     No  
9. Describe the primary actions of the drug/substance:Sodium channel blocker that acts to block neuronal impulses.  
 